The Capitol Forum's weekly health briefing also covers an interim pathway being discussed for wellness peptides.
Recap by typeshit. Post by The Capitol Forum on X.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
Clinics took about 60% of supply, and one Seoul clinic got more Mounjaro than 174 hospitals combined. The health ministry warns of sanctions and criminal referrals.
A short clip from an optometrist on reports linking GLP-1 medications to vision loss. Little detail beyond the topic itself.
Moss says he once believed GLP-1s caused far more muscle loss than ordinary calorie cutting. He now says he got that wrong.
Loading…